LOWETH COLIN J.,WIEMANN TORSTEN,GELBARD HARRIS A.,DEWHURST STEPHEN,RAVULA SATHEESH BABU,GOODFELLOW VAL S.
申请号：
NZ60364411
公开号：
NZ603644A
申请日:
2011.05.24
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
The disclosure relates to substituted imidazo-pyrazin-one derivatives of formula (VI) having an inhibitory effect on kinases including Mixed Lineage Kinases (MLK), wherein the variables are as defined in the specification. Also disclosed are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition, wherein said disease is chosen from diabetes mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, peripheral inflammation, cancer and hepatitis. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.
